SCRX Insider Trading Activity and SEC Form 4 Filings
SCRX insider trading summary
No open-market insider purchases or sales of Sciele Pharma, Inc. (SCRX) have been reported on SEC Form 4 in the past 12 months.
Latest SCRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 15, 2008 | Patrick Fourteau | Chief Executive Officer | Sell | $2.1M (100,000 @ $21.37) |
| Aug 11, 2008 | Larry Dillaha | EVP and Chief Medical Officer | Sell | $18K (875 @ $20.34) |
| May 23, 2008 | Jerry N Ellis | Director | Sell | $79K (3,750 @ $21.08) |
| May 23, 2008 | Jon S Saxe | Director | Sell | $79K (3,750 @ $21.08) |
| May 23, 2008 | Pierre Lapalme | Director | Sell | $79K (3,750 @ $21.08) |
| May 19, 2008 | Leslie Zacks | EVP/Chief Legal Compl. Officer | Sell | $35K (1,625 @ $21.71) |
| May 15, 2008 | Patrick Fourteau | Chief Executive Officer | Sell | $2.1M (100,000 @ $21.08) |
| Apr 25, 2008 | Larry Dillaha | EVP and Chief Medical Officer | Sell | $7K (350 @ $19.35) |
| Apr 3, 2008 | Edward J Schutter | President & COO | Sell | $52K (2,500 @ $20.72) |
| Mar 17, 2008 | Patrick J Zenner | Director | Buy | $18 (1 @ $18.49) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.